Stockscreener 앱 받기
7.94
3.52%
-0.29
시간 외 거래:
7.91
-0.03
-0.38%
전일 마감가:
$8.23
열려 있는:
$8.23
하루 거래량:
2.48M
Relative Volume:
1.56
시가총액:
$788.47M
수익:
$84.28M
순이익/손실:
$-171.30M
주가수익비율:
-4.5703
EPS:
-1.7373
순현금흐름:
$-171.21M
1주 성능:
+6.94%
1개월 성능:
-5.48%
6개월 성능:
+4.61%
1년 성능:
-45.32%
1일 변동 폭
$7.91
$8.29
1주일 범위
$7.08
$8.36
52주 변동 폭
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
7.94 | 817.27M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Northland Capital | Outperform |
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Should I Buy - Intellectia AI
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - The Globe and Mail
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
Earnings call transcript: ARS Pharmaceuticals misses Q1 2026 EPS forecast, stock drops - Investing.com
ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 - AlphaStreet
ARS Pharmaceuticals earnings missed by $0.12, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment - ChartMill
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell - Moomoo
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Investing News Network
ARS PHARMACEUTICALS ($SPRY) Releases Q1 2026 Earnings - Quiver Quantitative
ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary - TradingView
Neffy launch drives ARS Pharmaceuticals (NASDAQ: SPRY) Q1 revenue jump - Stock Titan
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss - Investing.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss - marketscreener.com
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q1 Revenue $22.7M, vs. FactSet Est of $22.2M - marketscreener.com
ARS Pharmaceuticals (NASDAQ: SPRY) grows neffy sales but posts $60.6M Q1 loss - Stock Titan
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo
ARS Pharmaceuticals Q1 2026 earnings preview - MSN
What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative - Kavout
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A - Benzinga
ARS Pharmaceuticals Appoints Donn Casale as New President - The Globe and Mail
ARS Pharma names Donn Casale president - The Pharma Letter
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates - Yahoo Finance
ARS Pharmaceuticals appoints Donn Casale as president By Investing.com - Investing.com India
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):